Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Tom Gordon who wrote (6585)	1/26/2001 7:35:50 PM
From: Montana Wildhack	Respond to of 14101

I didn't see that Tom. I keep wondering what made Acqua willing to buy up to 19.99% (.01 percent under the shareholder rights threshold, right Warren?). What is going on so that they said. "Sure we're willing to hold almost 8 million shares. A quick look tells us there's no way we could sell them except over an extended period of time and we'd kill the sharprice doing it - but we're comfortable with that." Dimethaid must have some pretty convincing sales projections in Europe. All I know is I was already comfortable that we're going to do well over the next year. Now with this Acqua decision, I know there's something big I'm not aware of. Something good. Is our projected market share so solid? Is the activity for the 50 million so compelling? Do they know something and have a plan for WF10? Are we buying somebody? Think about the size of the decision Acqua made. There is no way on god's earth they would do this without some very solid evidence or probability that something is going to be big. It ain't my $25 projection inside 18 months from a possible 4-5% European market share. You can forget about this stock going way down. It's not. Dave Poxon doesn't know the story; but, he saw the chart. Something new is coming after the quiet period. What it is can be speculated or rumoured about. That there is something is already clear. Wolf

To: Tom Gordon who wrote (6585)	1/26/2001 8:30:24 PM
From: DaveAu	Read Replies (1) \| Respond to of 14101

Tom, For those who missed the National, here's an article on the Glucosamine study: docguide.com Glucosamine Sulphate Proves Worth In Long-Term Osteoarthritis Trial A DGReview of :"Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial" Lancet 01/26/2001 By Harvey McConnell Long-term effects of glucosamine sulphate can moderate the symptoms and changes to joint structure associated with osteoarthritis. The symptom-modifying effects of glucosamine sulphate have been shown in several short- and medium-term clinical trials, and the drug has shown a good safety profile. There has been a need, however, for a long-term trial, points out lead researcher Dr. Jean Reginster, Bone and Cartilage Metabolism Unit, CHU Centre Ville, Liege, Belgium. Glucosamine sulphate is the sulphate derivative of the natural aminomonosaccharide glucosamine. Glucosamine, a normal constituent of glycosaminoglycans in cartilage matrix and synovial fluid, could have various pharmacological actions in articular cartilage and joint tissues. "In this study, glucosamine sulphate was approved as a prescription drug, therefore, our results cannot be generalized to other glucosamine products (or compound mixtures) such as those available in some countries as dietary supplements," the report points out. In a randomised, placebo-controlled trial with colleagues in Britain, Italy and the United States, the researchers randomized 212 patients with knee osteoarthritis to treatment with 1500 mg sulphate oral glucosamine or placebo once daily for three years. Weight bearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after one and three years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width at the narrowest point was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index groups. Researchers found no significant joint-space loss after three years in the 106 patients treated with glucosamine sulphate -- 0.06 mm. However, among the 106 patients on placebo there was a progressive joint-space narrowing, with a mean joint-space loss of 0·31 mm. Results were similar with minimum joint-space narrowing. Assessment by WOMAC scores found symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with glucosamine sulphate. Dr. Reginster and colleagues conclude that "further studies, with longer follow-up and different designs, are needed to assess whether these changes are predictive of further clinical progression of osteoarthritis -- eg, modifying the indication for possible joint surgery or the time to substantial disability." Dr. Tim McAlindon, Arthritis Center, Boston University Medical Center in a commentary said the study is a landmark in osteoarthritis research, emphasising the importance of the improved pain and disability scores in patients given glucosamine. Dr. McAlindon notes that glucosamine is available in many countries as a food supplement rather than as prescribed medication. "It is time for the [medical] profession to accommodate the possibility that many nutritional products may have valuable therapeutic effects and to regain the credibility of the public at large". Lancet 2001;357:251-56. "Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial"